NCT07062770 Assessment of Circuit Rebreathing During CPAP Therapy
| NCT ID | NCT07062770 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Brigham and Women's Hospital |
| Condition | Obstructive Sleep Apnea (OSA) |
| Study Type | INTERVENTIONAL |
| Enrollment | 13 participants |
| Start Date | 2025-05-27 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 13 participants in total. It began in 2025-05-27 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this research is to better understand how different CPAP mask designs affect airflow and rebreathing of exhaled carbon dioxide (CO₂) during sleep in individuals with obstructive sleep apnea (OSA).
Eligibility Criteria
Inclusion Criteria: * Moderate to severe OSA (AHI\>20) * Self-reported CPAP users or have previously used CPAP * Self-reported holding pressure of maximum 13 cmH2O (if known) * Age: 21-70 * BMI: 18-40 kg/m2 Exclusion Criteria: * Self-reported severe mouth-breathing * Requirement for nocturnal supplemental oxygen or other ventilatory support * Severe cardiovascular or pulmonary disease * Any unstable or acute medical condition * Any additional sleep disorder, including insomnia, except for OSA.
Contact & Investigator
Atqiya Aishah, PhD
PRINCIPAL INVESTIGATOR
Harvard Medical School & Brigham and Women's Hospital
Frequently Asked Questions
Who can join the NCT07062770 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Obstructive Sleep Apnea (OSA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07062770 currently recruiting?
Yes, NCT07062770 is actively recruiting participants. Contact the research team at aaishah@bwh.harvard.edu for enrollment information.
Where is the NCT07062770 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07062770 clinical trial?
NCT07062770 is sponsored by Brigham and Women's Hospital. The principal investigator is Atqiya Aishah, PhD at Harvard Medical School & Brigham and Women's Hospital. The trial plans to enroll 13 participants.